CD40 and neoplasm: The combination of intratumoural MPL and agonistic anti-CD40, which is known to activate macrophages, enhanced macrophage-induced killing of tumour cells, resulting in a significant increase in anti-tumour activity in mice compared to either treatment alone [36].